Literature DB >> 9832995

Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain.

R Depoortere1, G Perrault, D J Sanger.   

Abstract

In a previous study using Sprague-Dawley rats, we showed that in a prepulse inhibition (PPI) procedure with levels of PPI ranging from approximately 10 to 40% (for prepulse intensities 2, 9 and 15 dB above background noise), the antipsychotics clozapine and haloperidol, but also the alpha 1 adrenoceptor antagonist prazosin, robustly and dose-dependently potentiated PPI. In contrast, the antipsychotics risperidone, amisulpride, raclopride and remoxipride did not potentiate PPI. The false positive (prazosin) and the four false negatives led us to conclude that this PPI-enhancing procedure had poor predictive validity as a screening tool for potential antipsychotics. In the present study, we used Wistar rats, which under the same protocol as that used for Sprague-Dawley rats show a very low level of PPI. We examined the ability of six antipsychotics, given intraperitoneally (i.p.), to reverse this PPI deficit. It was found that clozapine (5-20 mg/kg), olanzapine (5-20 mg/kg) and sertindole (1-10 mg/kg) reversed this deficiency of PPI (i.e. potentiated the low level of PPI). In contrast, risperidone (0.1-1 mg/kg), remoxipride (1-10 mg/kg) and haloperidol (0.1-1 mg/kg) were inactive. The negative results with three clinically active antipsychotics (risperidone, remoxipride and haloperidol) indicate that reversal of this PPI deficit in Wistar rats has poor predictive validity to screen for potential antipsychotic activity. In an attempt to investigate the mechanism that might underlie the reversing effect of clozapine, olanzapine and sertindole, we tested the ability of the alpha 1 adrenoceptor antagonist prazosin (3-20 mg/kg), the dopamine D1 receptor antagonist SCH 23390 (0.01-0.1 mg/kg) and the 5-HT2 antagonist ritanserin (0.3-3 mg/kg) to reverse the PPI deficit. Negative results with these three drugs did not allow us to characterize the receptor(s) that might be implicated in the reversal of this type of PPI deficit.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9832995     DOI: 10.1097/00008877-199708000-00009

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  8 in total

1.  Developmental markers of psychiatric disorders as identified by sensorimotor gating.

Authors:  Susan B. Powell; Mark A. Geyer
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

2.  Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats.

Authors:  David Feifel; Paul D Shilling; Gilia Melendez
Journal:  Behav Neurosci       Date:  2011-04       Impact factor: 1.912

3.  Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

Authors:  Philipp A Csomor; Katrin H Preller; Mark A Geyer; Erich Studerus; Theodor Huber; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2014-05-07       Impact factor: 7.853

4.  Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients.

Authors:  Philipp A Csomor; Benjamin K Yee; Joram Feldon; Anastasia Theodoridou; Erich Studerus; Franz X Vollenweider
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

5.  CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.

Authors:  T N Douma; M J Millan; D Boulay; G Griebel; P M Verdouw; K G Westphal; B Olivier; L Groenink
Journal:  Psychopharmacology (Berl)       Date:  2013-11-02       Impact factor: 4.530

6.  Blockade of growth hormone secretagogue receptor 1A signaling by JMV 2959 attenuates the NMDAR antagonist, phencyclidine-induced impairments in prepulse inhibition.

Authors:  Jörgen A Engel; Elisabet Jerlhag; Lennart Svensson; Roy G Smith; Emil Egecioglu
Journal:  Psychopharmacology (Berl)       Date:  2015-08-29       Impact factor: 4.530

Review 7.  Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy.

Authors:  Fernanda F Peres; Raquel Levin; Valéria Almeida; Antonio W Zuardi; Jaime E Hallak; José A Crippa; Vanessa C Abilio
Journal:  Front Pharmacol       Date:  2016-09-09       Impact factor: 5.810

8.  The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.

Authors:  Guy Griebel; Jeanne Stemmelin; Mati Lopez-Grancha; Denis Boulay; Gerald Boquet; Franck Slowinski; Philippe Pichat; Sandra Beeské; Shinji Tanaka; Akiko Mori; Masatake Fujimura; Junichi Eguchi
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.